YAP1 and head and neck squamous cell carcinoma: In this regard, while VP cannot be considered a specific YAP1 inhibitor and is likely to impact several other molecular targets in addition to blocking TEAD-YAP1 interactions37,38, this FDA-approved agent decreased the expression of YAP1-regulated genes and its administration resulted in increased apoptosis, and decreased proliferation and HNSCC tumorigenesis in vivo, mimicking YAP1 knockdown in these cells.